ABVC Biopharma Inc (ABVC) - Total Assets
Based on the latest financial reports, ABVC Biopharma Inc (ABVC) holds total assets worth $21.06 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABVC Biopharma Inc (ABVC) net assets for net asset value and shareholders' equity analysis.
ABVC Biopharma Inc - Total Assets Trend (2002–2025)
This chart illustrates how ABVC Biopharma Inc's total assets have evolved over time, based on quarterly financial data.
ABVC Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
ABVC Biopharma Inc's total assets of $21.06 Million consist of 11.9% current assets and 88.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how ABVC Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is ABVC Biopharma Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABVC Biopharma Inc's current assets represent 11.9% of total assets in 2025, a decrease from 100.0% in 2002.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, up from 0.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
ABVC Biopharma Inc Competitors by Total Assets
Key competitors of ABVC Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ABVC Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.41 | 0.33 | 1.12 |
| Quick Ratio | 0.41 | 0.33 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.66 Million | $-4.38 Million | $539.15K |
ABVC Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between ABVC Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.54 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 179.3% |
| Total Assets | $21.06 Million |
| Market Capitalization | $26.41 Million USD |
Valuation Analysis
Above Book Valuation: The market values ABVC Biopharma Inc's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ABVC Biopharma Inc's assets grew by 179.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABVC Biopharma Inc (2002–2025)
The table below shows the annual total assets of ABVC Biopharma Inc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $21.06 Million | +179.34% |
| 2024-12-31 | $7.54 Million | -3.14% |
| 2023-12-31 | $7.78 Million | -28.80% |
| 2022-12-31 | $10.93 Million | -20.18% |
| 2021-12-31 | $13.70 Million | -7.24% |
| 2020-12-31 | $14.77 Million | +113.16% |
| 2019-12-31 | $6.93 Million | +7096.01% |
| 2018-12-31 | $96.27K | -98.54% |
| 2017-12-31 | $6.60 Million | +35321.24% |
| 2016-12-31 | $18.64K | -72.67% |
| 2015-12-31 | $68.23K | +5.63% |
| 2014-12-31 | $64.59K | -82.51% |
| 2011-12-31 | $369.40K | +25.67% |
| 2010-12-31 | $293.94K | -43.27% |
| 2009-12-31 | $518.17K | -65.50% |
| 2008-12-31 | $1.50 Million | +24.73% |
| 2007-12-31 | $1.20 Million | +1263.02% |
| 2006-12-31 | $88.34K | +39.35% |
| 2005-12-31 | $63.40K | -29.80% |
| 2004-12-31 | $90.31K | -17.90% |
| 2003-12-31 | $110.00K | +175.00% |
| 2002-12-31 | $40.00K | -- |
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more